Tumores de Pele

Diretriz | Linfomas cutâneos.

27 Abr, 2022 | 15:32h

S2k-Guidelines – Cutaneous lymphomas (ICD10 C82 – C86): Update 2021 – Journal of the German Society of Dermatology

---

Estudo randomizado | Pembrolizumabe vs. placebo como terapia adjuvante no melanoma estágio IIB ou IIC completamente ressecado.

5 Abr, 2022 | 11:56h

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)

---

Impacto global do melanoma cutâneo em 2020 e projeções para 2040.

1 Abr, 2022 | 12:14h

Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040 – JAMA Dermatology (gratuito por tempo limitado)

Editorial: Melanoma Epidemiology—Pivoting to Low- and Middle-Income Countries (gratuito por tempo limitado)

Comentário: Global Burden of Melanoma Considerable, Set to Rise by 2040 – HealthDay

---

Revisão | Achados em exames de imagem de tumores cutâneos malignos: correlação patológica.

25 Mar, 2022 | 15:37h

Imaging findings of malignant skin tumors: radiological–pathological correlation – Insights into Imaging

---

Estimativa do diagnóstico excessivo (overdiagnosis) de melanoma usando tendências entre pacientes negros e brancos nos EUA.

25 Mar, 2022 | 14:52h

Estimating Overdiagnosis of Melanoma Using Trends Among Black and White Patients in the US – JAMA Dermatology (link para o resumo – $ para o texto completo)

Comentário: Deadly form of skin cancer ‘overdiagnosed’ in some patients, study finds – UPI

 

Comentário do autor no Twitter (fio – clique para saber mais)

The wildest thing about this paper is we wrote it in 2017, then shelved it because of the initial push back in peer review. This experience taught me A LOT about when colleagues are ready to accept ideas that challenge their thinking. 🧵
1/9 https://t.co/hXDURXkwju

— Ade Adamson, MD MPP (@AdeAdamson) March 20, 2022

 

---

Vitamina B3, niacinamida e redução do risco de câncer de pele: o que dizem as pesquisas?

23 Mar, 2022 | 11:28h

Vitamin B3, niacinamide and reducing skin cancer risk: what does the research say? – The Conversation

Conteúdo relacionado: A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention – New England Journal of Medicine

---

Diretrizes NCCN | Câncer de pele de células escamosas, versão 1.2022.

7 Fev, 2022 | 13:37h

NCCN Guidelines Insights: Squamous Cell Skin Cancer, Version 1.2022 – Journal of the National Comprehensive Cancer Network

---

Diretriz | Fibroxantoma atípico (FXA) e sarcoma dérmico pleiomórfico (SDP).

4 Fev, 2022 | 16:39h

S1-guideline atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS) – Journal of the German Society of Dermatology

---

Estudo randomizado | Sirolimo com prednisolona vs. sirolimo em monoterapia para hemangiotelioma kaposiforme.

20 Jan, 2022 | 20:28h

Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial – Blood (link para o resumo – $ para o texto completo)

---

Estudo randomizado | Em pacientes com melanoma avançado não tratado, o tratamento com relatimabe e nivolumabe foi associado com aumento na mediana de sobrevida livre de progressão em comparação com nivolumabe isolado (10,1 meses vs. 4,6 meses).

13 Jan, 2022 | 11:47h

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Comentário: Relatlimab plus nivolumab improves progression-free survival in metastatic melanoma – University of Texas M. D. Anderson Cancer Center

 

Comentário no Twitter

The inhibition of two immune checkpoints, LAG-3 and PD-1, provided a greater benefit with regard to PFS than inhibition of PD-1 alone in patients with previously untreated metastatic or unresectable melanoma. https://t.co/idtOgksg74 pic.twitter.com/vx1W9O4Dh6

— NEJM (@NEJM) January 5, 2022

 

---